Public debate around tobacco harm reduction (THR) is increasingly shaped not only by science, but by how that science is communicated. As non-combustible nicotine products expand across global markets, the
As nicotine pouches gain market presence in the United States, regulators must understand not only who is using these products, but where and under what conditions they are being purchased.
Recent market analyses from multiple industry research groups indicate that nicotine pouches are among the fastest-growing segments within the broader nicotine alternatives category. Reports from Fact.MR, Euromonitor International, Grand View
Debates around tobacco harm reduction are increasingly shaped not only by emerging products and regulatory decisions, but by how science itself is communicated. A recent commentary on misinformation and “clickbait
The U.S. Food and Drug Administration’s ongoing review of modified risk tobacco product (MRTP) applications for ZYN nicotine pouches represents a pivotal moment in the regulation of non-combustible nicotine. At
Nicotine pouches remain at the centre of the global harm‑reduction conversation — and a major new peer‑reviewed review helps explain why. A new narrative review by Konstantinos Farsalinos in Internal
Nicotine policy is increasingly being shaped not only by legislators and regulators, but by the channels through which products are made available to adults. In several countries, pharmacies have emerged
The European Commission has confirmed that the EU Tobacco Policy Expert Group (TPEG) will formally conclude its mandate, even as work on the next revision of the Tobacco Products Directive
Recent commentary describing nicotine pouches as “a wolf in sheep’s clothing” reflects legitimate public-health concerns about youth uptake, long-term uncertainty, and nicotine dependence. However, the framing risks obscuring a critical
As nicotine pouches continue to attract regulatory attention, discussion has increasingly focused on isolated clinical observations and precautionary warnings, often without sufficient context on real-world use patterns or comparative risk.
Nicotine pouches continue to expand across multiple markets, even as regulatory scrutiny intensifies and public debate grows more polarised. This sustained growth is not accidental, nor is it driven by
A GINN Insight responding to recent Medscape coverage Nicotine pouches are increasingly positioned at the centre of a familiar policy tension: how to protect young people from nicotine initiation without